Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Current Deferred Tax Assets (2023 - 2025)

Ascentage Pharma Group International posted quarterly Current Deferred Tax Assets of $183.4 million for Q4 2025, up 328.35% year-on-year from $42.8 million in Q4 2024, and up 96.26% on a QoQ basis from $93.4 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 3 years of Current Deferred Tax Assets data on file, last reported at $183.4 million in Q4 2025.

  • For the quarter ending Q4 2025, Current Deferred Tax Assets rose 328.35% year-over-year to $183.4 million; the trailing twelve-month figure through Dec 2025 stood at $183.4 million (up 328.35% YoY), and the FY2025 full-year result was $186.0 million, up 341.48% from the prior year.
  • Current Deferred Tax Assets for Q4 2025 stood at $183.4 million, up from $93.4 million in the prior quarter.
  • Across five years, Current Deferred Tax Assets topped out at $183.4 million in Q4 2025 and bottomed at $42.8 million in Q4 2024.
  • The 3-year median for Current Deferred Tax Assets is $75.2 million (2025), against an average of $94.2 million.
  • The widest annual swing landed in 2024, when Current Deferred Tax Assets slipped 24.81%; it then surged 328.35% in 2025.
  • A 3-year view of Current Deferred Tax Assets shows it stood at $56.9 million in 2023, then declined by 24.81% to $42.8 million in 2024, then soared by 328.35% to $183.4 million in 2025.
  • The last three Current Deferred Tax Assets figures came in at $183.4 million (Q4 2025), $93.4 million (Q2 2025), and $42.8 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 183.40 Mn
Dec 31, 2025 183.40 Mn
Jun 30, 2025 93.45 Mn
Jun 30, 2025 93.45 Mn
Dec 31, 2024 42.82 Mn
Dec 31, 2024 42.82 Mn
Dec 31, 2023 56.94 Mn
Dec 31, 2023 56.94 Mn